Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Skye Bioscience Inc (SKYE)

Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,698
  • Shares Outstanding, K 32,057
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,570 K
  • EBIT $ -54 M
  • EBITDA $ -53 M
  • 60-Month Beta 2.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.92
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.28
  • Most Recent Earnings $-0.32 on 11/10/25
  • Next Earnings Date 03/19/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 288.13% (+101.26%)
  • Historical Volatility 108.16%
  • IV Percentile 52%
  • IV Rank 26.84%
  • IV High 806.91% on 12/05/25
  • IV Low 97.86% on 04/04/25
  • Expected Move (DTE 36) 1.5810 (164.24%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 79
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 3,413
  • Open Int (30-Day) 4,062
  • Expected Range 0.0000 to 2.5436

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.29
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.36
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -20.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6844 +40.65%
on 12/31/25
1.2000 -19.78%
on 12/17/25
-0.1174 (-10.87%)
since 12/15/25
3-Month
0.6844 +40.65%
on 12/31/25
1.6600 -42.01%
on 10/27/25
-0.5674 (-37.08%)
since 10/15/25
52-Week
0.6844 +40.65%
on 12/31/25
5.7500 -83.26%
on 06/27/25
-1.8574 (-65.87%)
since 01/15/25

Most Recent Stories

More News
Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE).

SKYE : 0.9626 (-5.63%)
Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE

NEW YORK , Jan. 14, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in  Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities...

SKYE : 0.9626 (-5.63%)
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

LOS ANGELES , Jan. 14, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE ) for violations...

SKYE : 0.9626 (-5.63%)
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Jan. 14, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Skye Bioscience, Inc. ("Skye"...

SKYE : 0.9626 (-5.63%)
FRIDAY DEADLINE: Berger Montague Advises Skye Bioscience, Inc. (NASDAQ: SKYE) Investors to Inquire About a Securities Fraud Class Action by January 16, 2026

PHILADELPHIA , Jan. 13, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE)...

SKYE : 0.9626 (-5.63%)
Skye Provides 2026 Corporate Outlook

CBeyond TM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate...

SKYE : 0.9626 (-5.63%)
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

NEW YORK , Jan. 11, 2026 /PRNewswire/ --

SKYE : 0.9626 (-5.63%)
SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025. Skye is a clinical stage biopharmaceutical...

SKYE : 0.9626 (-5.63%)
Investors who lost money on Skye Bioscience, Inc.(SKYE) should contact Levi & Korsinsky about pending Class Action - SKYE

NEW YORK , Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities...

SKYE : 0.9626 (-5.63%)
Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE).

SKYE : 0.9626 (-5.63%)

Business Summary

Skye Bioscience Inc. is a biopharmaceutical company. It is focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need. Skye Bioscience Inc., formerly known as Emerald Bioscience Inc., is based in San Diego, Calif.

See More

Key Turning Points

3rd Resistance Point 1.1048
2nd Resistance Point 1.0674
1st Resistance Point 1.0150
Last Price 0.9626
1st Support Level 0.9252
2nd Support Level 0.8878
3rd Support Level 0.8354

See More

52-Week High 5.7500
Fibonacci 61.8% 3.8149
Fibonacci 50% 3.2172
Fibonacci 38.2% 2.6195
Last Price 0.9626
52-Week Low 0.6844

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar